Generate Biomedicines, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
GENB$13.78-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands) (unaudited)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(61,714) | $(44,314) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization and accretion on marketable securities | (146) | (919) |
| Non-cash stock-based compensation | 6,395 | 4,744 |
| Non-cash lease expense | 2,094 | 1,339 |
| Depreciation and amortization | 3,273 | 3,414 |
| Changes in fair value of convertible preferred stock warrant liability | 363 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | (91) |
| Prepaid expenses and other current assets | (6,221) | (2,756) |
| Other assets | 2,045 | 1,400 |
| Accounts payable | 3,754 | (597) |
| Operating lease liabilities | (1,841) | (55) |
| Other long term liabilities | (117) | (117) |
| Accrued expenses and other liabilities | (21,049) | (6,405) |
| Deferred revenue | (7,224) | (8,819) |
| Net cash used in operating activities | (80,388) | (53,176) |
| Investing activities | ||
| Purchase of marketable securities | (321,153) | (77,350) |
| Purchases of property and equipment | (3,781) | (751) |
| Proceeds from sales and maturities of marketable securities | 65,000 | 153,633 |
| Net cash used in investing activities | (259,934) | 75,532 |
| Financing activities | ||
| Proceeds from issuance of convertible preferred stock, net of issuance costs | — | 21,973 |
| Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses | 369,289 | — |
| Contributions from non-controlling interests | 7,500 | 750 |
| Proceeds from exercise of stock options | 3,217 | 483 |
| Payments on finance lease obligations | (1,115) | (2,646) |
| Net cash provided by financing activities | 378,891 | 20,560 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 38,569 | 42,916 |
| Cash, cash equivalents and restricted cash at beginning of period | 126,038 | 181,831 |
| Cash, cash equivalents and restricted cash at end of period | $164,607 | $224,747 |
| Cash and cash equivalents, end of period | 160,575 | 220,607 |
| Restricted cash and cash equivalents (VIE) | — | 96 |
| Long-term restricted cash | 4,032 | 4,044 |
| Cash, cash equivalents and restricted cash at end of period | 164,607 | $224,747 |
| Supplemental disclosure of noncash investing and financing information: | ||
| Purchase of property and equipment included in the accounts payable and accrued liabilities | $25 | $59 |
| Vesting of restricted stock | — | 46 |
| Reclassification of warrant liability to equity upon initial public offering | 1,568 | — |
| Conversion of convertible preferred stock to common stock | 811,826 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.